Apr 27, 2009 - Ligand Pharmaceuticals Incorporated today announced that its partner Wyeth has received approval from the European Commission (EC) for CONBRIZA™ (bazedoxifene), a selective estrogen receptor modulator (SERM) for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.
The details can be read here.
No comments:
Post a Comment